ArticleOncoimmunology2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.Molecular cancer · 2023Review
- The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.Cancer discovery · 2022Article
- Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis.Inflammopharmacology · 2020Article
- Article
- Porcine NK Cells Stimulate Proliferation of Pseudorabies Virus-Experienced CD8Frontiers in immunology · 2018Article
- Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Nature immunology · 2017Article
- Immunological off-target effects of imatinib.Nature reviews. Clinical oncology · 2016Review
- PD-1 Blockade Expands Intratumoral Memory T Cells.Cancer immunology research · 2016Article
- A role for pre-mNK cells in tumor progression.Journal for immunotherapy of cancer · 2016Article
- Natural killer cell mediated immunosurveillance of pediatric neuroblastoma.Oncoimmunology · 2015Article
- c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.Cancer immunology research · 2014Article
- Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology · 2014Review
- A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.Journal of the National Cancer Institute · 2014Review
- Trial Watch: Chemotherapy with immunogenic cell death inducers.Oncoimmunology · 2014Review
- Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells.Frontiers in immunology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a Phase I clinical trial from October 2007 to October 2009, enrolling patients affected by refractory solid tumors, to determine the maximum tolerated dose (MTD) of interleukin (IL)-2 combined with low dose cyclophosphamide (CTX) and imatinib mesylate (IM). In a companion paper published in this issue of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.